Class / Patent application number | Description | Number of patent applications / Date published |
514717000 | Benzene ring containing | 84 |
20090156687 | Fab I and inhibition of apicomplexan parasites - Discovery and characterization of an apicomplexan Fab I gene and encoded enzyme and discovery of the triclosan as a lead compound, provide means to rationally design novel inhibitory compositions useful for prevention and treatment of apicomplexan related diseases. | 06-18-2009 |
20090258951 | Use of vanillyl alcohol for the treatment of Parkinson's disease - A use of Vanillyl alcohol for treatment of Parkinson's disease is disclosed in accordance with the present invention. The Vanillyl alcohol's formula is 4-hydroxy-3-methoxy-benzyl alcohol and similitude with the human neurotransmitter dopamine. The Vanillyl alcohol has dopamine receptor stimulant and which is applied for pharmaceutical preparation of treating Parkinson's disease. | 10-15-2009 |
20100249246 | Therapeutic Compounds - A (−)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, is useful as an anesthetic. | 09-30-2010 |
20120010298 | Method for synthesizing (E)-Anethol and Related Compounds By Cross Coupling Reaction of Potassium alllyltrifluroborate and 4-bromoanisole and aryl halides - Methods of producing substituted and non-substituted beta-methyl styrene by a cross-coupling reaction are provided. The disclosure also provides for methods of preparing (E)-Anethol and related compounds by a cross coupling reaction of potassium allyltrifluoroborate and 4-bromoanisole and aryl halides. Compounds, compositions, and methods of treating disorders utilizing beta-methyl styrene are also provided. | 01-12-2012 |
20130005829 | Segmented, epsilon-Caprolactone-Rich, Poly(epsilon-Caprolactone-co-p-Dioxanone) Copolymers for Medical Applications and Devices Therefrom - Novel semi-crystalline, epsilon-caprolactone-rich block copolymers of epsilon-caprolactone and p-dioxanone for long term absorbable medical applications are disclosed. The novel polymer compositions are useful for long term absorbable surgical sutures, and other medical devices. Also disclosed are compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease. | 01-03-2013 |
20140275284 | DIPHENYL SUBSTITUTED CYCLOHEXANE DERIVATIVES, USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS BETA - Disclosed herein are novel di-aromatic compounds of the general formula (I). Also pharmaceutical compositions comprising the novel compounds and the use of the novel compounds in treatment and prevention of diseases and disorders related to estrogen receptors are disclosed. Furthermore, methods for treating and preventing diseases and disorders related to estrogen receptors by administration of the novel compounds are disclosed. | 09-18-2014 |
20140336270 | Method for synthesizing (E)-Anethol and Related Compounds By Cross Coupling Reaction of Potassium allyltrifluroborate and 4-bromoanisole and aryl halides - Methods of producing substituted and non-substituted beta-methyl styrene by a cross-coupling reaction are provided. The disclosure also provides for methods of preparing (E)-Anethol and related compounds by a cross coupling reaction of potassium allyltrifluoroborate and 4-bromoanisole and aryl halides. Compounds, compositions, and methods of treating disorders utilizing beta-methyl styrene are also provided. | 11-13-2014 |
514718000 | Plural oxygens | 77 |
20090069443 | Sedative Effect-Imparting Agent And Sedative Perfume Composition Containing The Same - It is intended to provide a sedative effect-imparting agent that provides excellent sedative effect with good fragrance-releasing property, and is possible to provide the excellent sedative effect immediately. | 03-12-2009 |
20090082471 | DEUTERIUM-ENRICHED FINGOLIMOD - The present application describes deuterium-enriched fingolimod, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20100197803 | METHOD FOR OBTAINING A SEQUOYITOL-CONTAINING EXTRACT FROM A PLANT OF THE GENUS OF TRIFOLIUM, LEGUMINOSAE OR GINKOACEAE AND USES THEREOF - The method for obtaining a sequoyitol-containing extract from a plant of the genus of | 08-05-2010 |
20100331426 | Synergistic preparations based on mixtures of glycerol ether with aromatic alcohol for controlling mycobacteria - Disinfectant which has activity towards mycobacteria and has (a) 1-(2-ethylhexyl} glycerol ether and (b) one or more aromatic alcohols group including aryloxyalkanols, ethers and arylalkanols. | 12-30-2010 |
20120010299 | Non-prescription medicine, vital fluid, and/or nutritional supplement - The present invention is directed toward a method of administering an oral solution containing one or more active ingredients, preferably formulations for non-prescription medicines, vital fluids, and/or nutritional supplements, optimally dosed based upon a patient's weight. The method includes providing an oral solution having an effective amount of one or more active ingredients; determining the weight of the individual, preferably to an individual less than 12 years old; and administrating an appropriate amount of the oral solution in a single dose dispensing unit in accordance with the weight determination of the individual, whereby the total amount of active ingredient administered corresponds to an effective amount of the active ingredient based on the individual's weight. | 01-12-2012 |
20130303629 | ANTIOXIDANT, ANTIOXIDANT COMPOSTION AND PRODUCTION METHOD THEREFOR - Problem To provide an antioxidant, an antioxidant composition, and a method for producing the antioxidant and the antioxidant composition, which feature a high content rate and degree of extraction of substances. These substances are taurine, glycogen, protein, so-called blood platelet anticoagulant with zinc, fat-soluble vitamin with a high activation such as vitamin D, and other useful substances. The antioxidant and the antioxidant composition also feature a so-called antioxidative property, which has recently attracted attention. | 11-14-2013 |
20150148430 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS - The present disclosure provides phenolic compounds useful in the treatment of neurological conditions such as convulsions and tremors, having the structure of Formula (I): | 05-28-2015 |
514719000 | Alicyclic ring | 9 |
20090036542 | Hydroquinone Long-Chain Derivative and/or Phenoxy Long-Chain Derivative and Pharmaceutical Comprising Same - The present invention provides compounds represented by formula (1) shown below: | 02-05-2009 |
20090069444 | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration - Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight. | 03-12-2009 |
20090170956 | PREPARATION AND THE USE OF ETHOXY COMBRETASTATINS AND THEIR PRODRUGS - The invention disclosed a total synthesis process of novel ethoxy combretastatins and their prodrugs. Combretastatins are chemically modified by ethoxy substituted on the 4′-position of their B aryl ring and are converted to be their soluble prodrugs of phosphate or their inner salt of phosphorylcholine by modifying the hydroxyl on the 3′-position of their B aryl ring. Similarly, 3′-amino combretastatin is 4′-ethoxy chemically modified and further side chain of amino acid can be introduced to the amino to form soluble prodrug of amino acidamide. The structure of the said compound is showed as formula (I). Ethoxy combretastatins possess potent tubulin polymerization inhibitory activity and can be used for the treatment of inhibiting tumor or neovascular. | 07-02-2009 |
20090215908 | TOLL LIKE RECEPTOR (TLR) SIGNALING ANTAGONIST - The present invention relates to novel synthetic toll like receptor antagonist. The present invention in particular provides compounds, methods and compositions for specifically inhibiting immune stimulation involving TLR ligands, especially TLR-4. The compounds are potentially useful in treatment of inflammation, autoimmunity, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency. | 08-27-2009 |
20090239955 | Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient - Disclosed herein are novel obovatol derivatives represented by Chemical Formula 1, and pharmaceutically acceptable salts thereof. Having the ability to inhibit the growth of cancer cells and induce apoptosis in cancer cells, the derivatives or pharmaceutically acceptable salts thereof are useful in the prevention and treatment of cancer and in the suppression of cancer metastasis. Also, a method for preparing the derivatives, and pharmaceutical compositions comprising the derivatives as active ingredients are disclosed. | 09-24-2009 |
20100222438 | METHODS COMPOSITIONS AND ARTICLE OF MANUFACTURE FOR MODULATING BONE GROWTH - Novel methods and pharmaceutical compositions suitable for modulating bone growth and remodeling, preventing bone diseases, inducing bone growth or repair by cannabinoid receptor-mediated effects on bone cells is disclosed. Methods of identifying bone growth modulating agents are also disclosed. | 09-02-2010 |
20110124741 | RADIOSENSITIZER COMPOSITIONS COMPRISING SCHISANDRA CHINENSIS(TURCZ.)BAILL AND METHODS FOR USE - The present invention provides a method of potentiating radiation therapy for treatment of a cancer or tumor comprising administrating to a subject in need thereof a therapeutically effective amount of a radiosensitizer in combination of a radiation therapy to a locus of the cancer or tumor, wherein the radiosensitizer is an extract of | 05-26-2011 |
20110269842 | COMPOSITIONS COMPRISING CB RECEPTOR AGONISTS, USES THEREOF AND METHODS FOR THEIR PREPARATION - Provided are compositions including (3R, 4R, 6R)-stereoisomers of phenyl substituted pinenes having CB receptor agonist properties, methods of treating diseases or disorders with the pharmaceutical compositions, and processes for their preparation are also provided. | 11-03-2011 |
20130184353 | MATERIALS AND METHODS FOR REDUCTION OF PROTEIN TAU AND TREATMENT OF NEURODEGENERATIVE DISEASES - The subject invention provides a myricanol compound that is in predominant form of (+)-αR,11S-myricanol as compared to (−)-αS,11R-myricanol. In one embodiment, the (+)-αR,11S-myricanol is isolated from | 07-18-2013 |
514720000 | Acyclic carbon to carbon unsaturation | 40 |
20090163600 | Anti-Inflammatory Agent and Cancer-Preventive Agent Comprising Canolol or Prodrug Thereof and Pharmaceutical, Cosmetic and Food Comprising the Same - An anti-inflammatory agent or cancer-preventive agent comprising 4-vinyl-2,6-dimethoxyphenol of the formula (1): or a PD thereof. | 06-25-2009 |
20100041768 | COMPOSITION AND METHOD OF ADIPOSE CELL DIFFERENTIATION INHIBITION - The present invention is related to a composition and method of adipose cell differentiation inhibition. | 02-18-2010 |
20100160450 | METHODS OF REDUCING 15-F2T-ISOP LEVELS IN MAMMALS - Methods of reducing 15-F2t-IsoP levels in mammalian subjects are disclosed herein. In addition, methods of reducing or preventing oxidative stress and treating or preventing related diseases are disclosed. | 06-24-2010 |
20100160451 | METHODS AND COMPOSITIONS FOR CONTROL OF CABBAGE LOOPER, Trichoplusia ni - The invention provides in part dialkoxybenzene compounds for controlling infestation by a | 06-24-2010 |
20100204339 | Orally Bioavailable Stilbenoids- Compositions and Therapeutic Applications Thereof - Disclosed is a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#I. Also disclosed is an anti-acne composition comprising 3,5-dimethoxy- 3,4′-dihydroxystilbenes represented by STR#I. Further, a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 2,3′,5′, 6-tetrahydroxy-trans-stilbene represented by STR#II is also disclosed. | 08-12-2010 |
20100204340 | ORALLY BIOAVAILABLE STILBENOIDS- COMPOSITIONS AND THERAPEUTIC APPLICATIONS THEREOF - A novel, bioavailable and safe stilbenoid 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 with an unexpected enhanced ability to prevent the accumulation of lipids accompanying the terminal differentiation of adipocytes, thereby inhibiting adipogenesis, and nutraceutical and cosmeceutical compositions comprising 3,5-dimethoxy-3,4′-dihydroxystilbene useful for anti-obesity and anti-cellulite therapy, are disclosed. Further the enhanced SIRT-1 activation ability of 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#1 and 2,3′,5′,6-tetrahydroxy-trans-stilbene represented by STR#II are disclosed. The enhancement of SIRT-1 polypeptide activity of the said compounds is unexpectedly much higher than resveratrol or its natural analog pterostilbene. Sirtuin modulating compositions comprising an orally bioavailable SIRT-1 enhancing compounds (i) 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#I and (ii) 2,3′,5′,6-tetrahydroxy-trans-stilbene represented by STR#II are also disclosed. An additional embodiment, also discloses the enhanced anti-Propionibacterium acnes activity of 3,5-dimethoxy-3,4′-dihydroxystilbenes represented by STR#I and compositions thereof. | 08-12-2010 |
20100240767 | Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof - Disclosed is the cosmeceutical potential of 3,5-dimethoxy-4′-hydroxystilbene in terms of its melanogenesis inhibitory and photo protective activities. Also disclosed does a topical melanogenesis inhibitory composition comprising 0.01 to 50% by weight of 3,5-dimethoxy-4′-hydroxystilbene. | 09-23-2010 |
20100280131 | METHODS FOR THE INHIBITION OF ATROPHY OR FOR TREATMENT OR PREVENTION OF ATROPHY-RELATED SYMPTOMS IN WOMEN - This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) | 11-04-2010 |
20100324149 | Methods And Compositions For Prevention And Treatment Of Inflammatory Disease, Autoimmune Disease, and Transplant Rejection - The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection. | 12-23-2010 |
20110046235 | PRODUCTS COMPRISING, AND USES OF, DECARBOXYLATED PHENOLIC ACIDS DERIVED FROM CHLOROGENIC ACIDS OF COFFEE - The present invention relates to uses of decarboxylated phenolic acid derived from chlorogenic acid of coffee as well as products comprising decarboxylated phenolic acid derived from chlorogenic acid of coffee, especially a coffee extract, and methods of producing such products. Coffee comprises chlorogenic acids, according to the invention these chlorogenic acids can be transformed into decarboxylated phenolic acids. The resulting decarboxylated phenolic acids have antioxidant and/or anti-inflammatory properties and can be used as ingredients in food and beverage products and to treat certain health conditions. | 02-24-2011 |
20110060060 | Pterostilbene as a New Agonist for the Peroxisome Proliferator-Activated Receptor Alpha Isoform - Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. Resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) were evaluated for their effects on the activation of the peroxisome proliferator-activated receptor alpha (PPARα) isoforms, a receptor shown to mediate the activity of lipid-lowering drugs such as the fibrates. The four stilbenes and ciprofibrate (positive control) were evaluated for the activation of endogenous PPARα in H4IIEC3 cells. Pterostilbene demonstrated the highest induction of PPARα demonstrating increases of 7- and 9-14 fold relative to control. The maximal responses to pterostilbene are similar to those obtained with the hypolipidemic drug, ciprofibrate; that is, pterostilbene acts as a PPARα agonist, like that of the fibrate class, and is a more effective hypolipidemic agent than resveratrol. | 03-10-2011 |
20110124742 | COMPOSITION AND METHOD OF ADIPOSE CELL DIFFERENTIATION INHIBITION - The present invention is related to a composition and method of adipose cell differentiation inhibition. | 05-26-2011 |
20110144212 | KEY INTERMEDIATE FOR THE PREPARATION OF STILBENES, SOLID FORMS OF PTEROSTILBENE, AND METHODS FOR MAKING THE SAME - The present invention provides a scalable process for the preparation of stilbenes by (i) condensing 3,5-dialkylbenzyl phosphonates with 4′-O-tetrahydropyranyl benzaldehyde to get 3,5-alkyl-4′-O-tetrahydropyranyl Stilbene and (ii) deprotecting the obtained 3,5-Dialkyl-4′-O-tetrahydropyranylstilbene to yield stilbenes. The present invention also provides a novel intermediate 3,5-Dialkyl-4′-O-tetrahydropyranyl stilbene, which is a key intermediate for the synthesis of stilbenes such as Pterostilbene and Resveratrol. The present invention also provides characteristics of various solid forms of Pterostilbene, methods for their preparation, as well as dosage forms containing the same for administration to or consumption by humans. | 06-16-2011 |
20110218250 | COMPOSITION BASED ON GLYCEROL ETHER/POLYOL MIXTURES - The invention relates to compositions which comprise one or more glycerol ethers together with one or more diol/diols and/or polyol/polyols. As a result, as well as good microbicidal effectiveness, whitening is reduced or avoided, drying-out of the skin is prevented, the moisture content is regulated and the skin is regreased to an adequate extent. | 09-08-2011 |
20120071561 | Methods And Compositions For Prevention And Treatment Of Inflammatory Disease, Autoimmune Disease And Transplant Rejection - The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection. | 03-22-2012 |
20120122995 | Anti-Inflammatory Agent and Cancer-Preventive Agent Comprising Canolol or Prodrug Thereof and Pharmaceutical, Cosmetic and Food Comprising the Same - An anti-inflammatory agent or cancer-preventive agent comprising 4-vinyl-2,6-dimethoxyphenol of the formula (1): or a PD thereof. | 05-17-2012 |
20120270952 | METHOD FOR ENHANCING THE BIOAVAILABILITY OF OSPEMIFENE - This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) | 10-25-2012 |
20120289605 | METHOD FOR INDUCING UDP-GLUCURONOSYLTRANSFERASE ACTIVITY USING PTEROSTILBENE - A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene. | 11-15-2012 |
20130131185 | Methods and Compositions for Control of Cabbage Looper, Trichoplusia ni - The invention provides in part dialkoxybenzene compounds for controlling infestation by a | 05-23-2013 |
20130150455 | METHOD FOR TREATING MECHANICAL ALLODYNIA COMPRISING ADMINISTRATION OF EUGENOL - The present invention relates to a pharmaceutical composition for selectively treating mechanical allodynia, which provides eugenol or a pharmaceutically acceptable salt thereof at a concentration lower than that which would inhibit voltage-gated sodium channels (VGSCs), a pharmaceutical composition for blocking hyperpolarization-activated current (I | 06-13-2013 |
20130217782 | Orally bioavailable stilbenoids-Compositions and therapeutic applications thereof - Disclosed is a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 3,5-dimethoxy-3,4′-dihydroxystilbene represented by STR#I. Also disclosed is an anti-acne composition comprising 3,5-dimethoxy-3,4′-dihydroxystilbenes represented by STR#I. Further, a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 2,3′,5′,6-tetrahydroxy-trans-stilbene represented by STR#II is also disclosed. | 08-22-2013 |
20130296441 | Anti-Obesity Properties of Pterostilbene - We have determined that pterostilbene demonstrates anti-obesity properties. Rats were fed a commercial obesogenic diet supplemented or not with pterostilbene: PT15 (low dose: 15 mg/kg body weight/d) or PT30 (high dose: 30 mg/kg body weight/d) for 6 weeks. Pterostilbene significantly reduced total adipose tissue mass (15.1% in the PT15 group; 22.9% in the PT30 group) without changes in food intake. The activities of lipogenic enzymes were reduced in white adipose tissue and liver. Activities of enzymes involved in liver fatty acid oxidation were significantly increased in the PT30 group. Low dose pterostilbene can reduce body fat by reducing lipogenesis in adipose tissue. At the high dose, two mechanisms contribute to reduction in body fat: (1) decrease in adipose tissue and liver lipogenesis, and (2) an increase in liver fatty acid oxidation. | 11-07-2013 |
20130324614 | METHOD FOR ENHANCING THE BIOAVALABILITY OF OSPEMIFENE - This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) | 12-05-2013 |
20140107223 | TOPICAL UBIQUINOL SUPPLEMENT SKIN CARE COMPOSITIONS - Topical, UBIQUINOL supplement compositions useful for treating skin by: reducing oxidative stress, adjunctively restoring “local” UBIQUINOL levels, revitalizing aged and/or U.V. damaged skin and regulating immune responses, including responses to inflammatory challenges; comprising: stabilized UBIQUINOL supplement, an emulsion of polydimethylsiloxane in a nonionic surfactant and skin penetrants. | 04-17-2014 |
20140163116 | METHOD OF TREATING CANCER USING A CURCUMIN DERIVATIVE - The present invention is directed to treating cancer with a compound represented by Structural Formula (I): | 06-12-2014 |
20140256827 | Method Improve Spatial Memory Via Pterostilbene Administration - Disclosed is a pharmaceutical composition for treating oxidative stress comprising a therapeutically effective amount of a substantially pure compound of pterostilbene and a physiologically acceptable carrier. Pterostilbene is administered in an amount between about 2.5 mg to about 10 mg per kilogram of subject body weight. Also disclosed is a method for increasing a working memory of a subject, the method comprising administrating an effective amount of a substantially pure compound of pterostilbene, wherein the working memory for a subject increase and the therapeutic effectiveness is about 10 mg of pterostilbene per kilogram of subject body weight. | 09-11-2014 |
20140303259 | METHOD FOR ENHANCING THE BIOAVAILABILITY OF OSPEMIFENE - This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) | 10-09-2014 |
20140329910 | Cooling Agent and TRPM8 Activator - Provided are a cooling agent having an excellent TRPM8 activating action, a TRPM8 activator, a method for imparting cooling sensation, and a novel compound useful for imparting cooling sensation. Disclosed is a cooling agent comprising, as an active ingredient, a compound represented by the following formula (1): | 11-06-2014 |
20150011650 | METHOD FOR TREATING NON-MELANOMA SKIN CANCER BY INDUCING UDP-GLUCURONOSYLTRANSFERASE ACTIVITY USING PTEROSTILBENE - A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene. | 01-08-2015 |
20150051295 | USE OF PROPANOL AND PROPENOL DERIVATIVES AS ANTIOXIDANTS - The invention relates to the use of propanol and propenol derivatives as antioxidants, to compositions comprising propanol and propenol derivatives and the preparation thereof, and to certain propanol and propenol derivatives and the preparation thereof. | 02-19-2015 |
20150057366 | SYNTHESIS OF ELEMICIN AND TOPICAL ANALGESIC COMPOSITIONS - The present invention is directed to the synthesis of elemicin and its isomeric form, and their use in topical analgesic formulations, including for dental and veterinary use. Various compositions include gels, films, dressings, cavity filling gels, having analgesic and/or antifungal properties. | 02-26-2015 |
20150307429 | PRENYLATED HYDROXYSTILBENES - Prenylated stilbene compounds and the use of such compounds in the treatment of diseases and medical disorders, for example cancer, skin ageing, inflammation, bacterial or fungal infection and immunosuppression. | 10-29-2015 |
20150343112 | LIQUID BANDAGE - According to at least one exemplary embodiment, a composition for a liquid bandage may be described, and may include a composition for a colored liquid bandage. The liquid bandage may be applied to protect an affected area. Additionally, one exemplary embodiment may include a method for making a composition for a liquid bandage. Additionally, one exemplary embodiment may include a method for applying a liquid bandage. Additionally, one exemplary embodiment may include a method for removing a liquid bandage. | 12-03-2015 |
20160058712 | 3-HYDROXYPTEROSTILBENE AND THERAPEUTIC APPLICATIONS THEREOF - The invention discloses the therapeutic potential of 3,4-dihydroxy-3′,5′-dimethoxy-trans-stilbene(3-hydroxypterostilbene or 3-HPT) in colon cancer and prostate cancer. | 03-03-2016 |
20160067192 | Anxiolytic Effect of Pterostilbene - We report for the first time that pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the Elevated-plus maze (EPM) test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by an increase in percent permanence time and number of entries in open arms, critical determinants correlated with anxiety. This anxiolytic activity of pterostilbene was comparable to that of diazepam at 1 and 2 mg/kg in the EPM. The percent traveled distance and the percent permanence time in the enclosed arms were decreased with the 1 and 2 mg/kg doses. The 5 and 10 mg/kg doses did not show any anxiolytic effect. Locomotor activity was unaffected in all doses. Western blot analysis corroborated the observed behaviors in the EPM, revealing a decrease in both ERK1 and ERK2 phosphorylation in hippocampal homogenates from mice treated with 1 and 2 mg/kg doses; the 5 and 10 mg/kg doses showed no significant effect on the phosphorylation of ERKs. Pterostilbene was detected in serum and brain tissue following a single oral administration, demonstrating that the compound can cross the blood-brain barrier to reach the brain regions, including hippocampus, and thereby exert its anxiolytic effect. Resveratrol, the parent molecule of pterostilbene, did not have any anxiolytic effect. | 03-10-2016 |
20160067193 | TOPICAL PTEROSTILBENE COMPOSITIONS FOR USE IN TREATING UV-INDUCED SKIN DAMAGE AND HYPERPLASIA - A chemoprotective method for treating, inhibiting or preventing DNA damage in skin and/or hyperplasia caused by ultraviolet (UV) light by using an effective amount of pterostilbene is provided. Pharmaceutical and nutraceutical compositions containing pterostilbene suitable for administration to an individual in order to prevent subsequent UV-mediated DNA damage and/or hyperplasia in skin are provided. | 03-10-2016 |
20160067194 | TOPICAL PTEROSTILBENE COMPOSITIONS FOR USE IN TREATING UV-INDUCED LOSS OF BARRIER FUNCTION IN SKIN - A chemoprotective method for treating, inhibiting or preventing loss of barrier function in skin caused by ultraviolet (UV) light by using an effective amount of pterostilbene is provided. Pharmaceutical and nutraceutical compositions containing pterostilbene suitable for administration to an individual in order to prevent subsequent UV-mediated loss of barrier function in skin are provided. | 03-10-2016 |
20160101065 | METHOD FOR ENHANCING THE BIOAVAILABILITY OF OSPEMIFENE - This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) | 04-14-2016 |
20160152538 | REPELLENT EFFECTIVE AGAINST ANOPHELES GAMBIAE | 06-02-2016 |
20160158163 | Method For Treating Gefitinib-Resistant Non-Small-Cell Lung Cancer - The present invention relates to a method for treating gefitinib-resistant non-small-cell lung cancer (NSCLC) comprising administering an effective amount of a resveratrol analogue, (Z)3,4,5,4′-tetramethoxystilbene (TMS), to a subject in need thereof. The present invention also relates to a method for inducing apoptosis in gefitinib-resistant NSCLC cells comprising contacting the resveratrol analogue to the cells at an effective amount. The present methods are mediated by different signaling pathways connected to cell proliferation and differentiation such as mTOR, JNK, and certain EGFR phosphorylated tyrosine kinase. | 06-09-2016 |
514721000 | Plural benzene rings | 21 |
20080280994 | Ascophyllum Compositions and Methods - The invention provides extracts of brown seaweed of the genus | 11-13-2008 |
20080293824 | Pesticidal substituted piperidines - The invention relates to the use of phenylether derivatives of formula (I), to compositions thereof for the control of pests, including arthropods and helminths. | 11-27-2008 |
20090036543 | Preservatives - The present invention relates to the use of compounds of the formula (1) wherein all substitutents have the meanings as defined in claim | 02-05-2009 |
20090143482 | Pesticidal Substituted Phenylethers - The invention relates to the use of phenylether derivatives of formula (I), to compositions thereof for the control of pests, including arthropods and helminths. | 06-04-2009 |
20090176889 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I) wherein n is 1 or 2; q is 0 or 1; t is 0 or 1; R | 07-09-2009 |
20100048731 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents - The present invention relates to a compound of general formula (I) below in which R | 02-25-2010 |
20100093872 | STABLE AQUEOUS FORMULATIONS OF WATER INSOLUBLE OR POORLY SOLUBLE DRUGS - A novel pharmaceutical formulation and process for manufacturing an aqueous based formulation of drugs with low or no water solubility. The drug is combined with the inclusion carrier cyclodextrin, eliminating the need for using organic solvents, to combine the drug, in an aqueous solution of cyclodextrin and heating the resulting mixture above its melting point and allowing the drug to be drawn into the cyclodextrin. | 04-15-2010 |
20100152303 | AGENTS AND METHOD FOR INCREASING BRAIN CHAPERONIN LEVELS - The invention includes; a method of modulating a level of chaperone protein, a method of modulating a level of ERP57, a method of alleviating a symptom of a disease associated with decreased levels of chaperone proteins, and a method of alleviating a symptom of Alzheimer's disease. The methods include administering to a patient a substituted biphenylmethane compound. Preferably the compound is an analog to methoxychlor. More preferably the compound is methoxychlor. The invention also includes pharmaceutical compositions. The pharmaceutical compositions include substituted biphenylmethanes and a pharmaceutically acceptable carrier. Preferably the pharmaceutical compositions include methoxychlor analogs and a pharmaceutically acceptable carrier. More preferably the pharmaceutical compositions include methoxychlor and a pharmaceutically acceptable carrier. | 06-17-2010 |
20100267839 | Diarylalkanes as potent inhibitors of binuclear enzymes - The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto. The method for preventing and treating diseases and conditions related to binuclear enzyme function and melanin overproduction is comprised of administering to a host in need thereof an effective amount of a composition comprising one or more diarylalkanes and/or diarylalkanols synthesized and/or isolated from one or more plants together with a pharmaceutically acceptable carrier. | 10-21-2010 |
20100286285 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state - The present invention relates to an anhydrous pharmaceutical composition for use in the treatment of psoriasis and other skin disorders, characterized in that it comprises an oleaginous ointment and, as active ingredient, a compound chosen from vitamin D and its derivatives, said active agent being in a solubilized form in said composition. | 11-11-2010 |
20110105624 | ENDIPALENE FORMULATIONS IN THE TREATMENT OF PSORIASIS - The present invention relates to the field of molecules suitable for treatment of inflammation through inhibitory actions in one or more steps of the Arachidonic Acid pathway. Specifically the present invention provides an improvement in the use of Endipalene molecules as anti-inflammatory pharmaceutical agents, more specifically as 5-lipoxygenase inhibitor agents, for treating inflammation and inflammation-related skin disorders. | 05-05-2011 |
20110130467 | METHOD FOR PRODUCING ANTIMICROBIAL-CONTAINING SOLUTION - A method for producing an antimicrobial-containing solution includes mixing an alkaline aqueous solution which dissolves a phenol-based antimicrobial, and has a pH of 9 or higher and acid which has a pH 6 or lower. | 06-02-2011 |
20110144213 | ANHYDROUS DEPIGMENTING COMPOSITIONS COMPRISING A SOLUBILIZED PHENOLIC COMPOUND - Novel anhydrous dermatological depigmenting compositions, especially for topical application, contain, as pharmaceutical active agent, a phenolic compound dissolved in a fatty phase therefor. | 06-16-2011 |
20110207830 | COMPOSITION FOR TREATING OR PREVENTING AMYLOID-RELATED DISEASES COMPRISING 4-O-METHYLHONOKIOL - Disclosed is a composition for treating or preventing amyloid-related diseases including 4-O-methylhonokiol as an active ingredient. More specifically, a pharmaceutical composition including 4-O-methylhonokiol, which is effective for treating or preventing amyloid-related diseases such as Alzheimer's disease, cognitive disorder, defective memory, amyloidosis, etc. is disclosed. The inventors of the present disclosure have found out for the first time that 4-O-methylhonokiol inhibits the production of β-amyloid. It has been confirmed to be useful in treating or preventing amyloid-related diseases. Through animal tests including water maze test and passive avoidance test on mice, 4-O-methylhonokiol has been confirmed to be effective for amyloid-related diseases such as Alzheimer's disease, defective memory, cognitive disorder, and the like. It was further confirmed through acetylcholinesterase activity inhibition test using mouse brain cortex and hippocampus tissue that they are particularly effective in treating or preventing Alzheimer's disease among the amyloid-related diseases. | 08-25-2011 |
20130210928 | NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARING NOVEL BIPHENYL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING DIABETES COMPLICATIONS - The present invention provides a novel biphenyl compound or pharmaceutically acceptable salts thereof, methods for preparing the same, and pharmaceutical compositions for preventing or treating diabetic complications containing the same as an active ingredient. Novel biphenyl compounds, according to the present invention, effectively suppress generation activity of advanced glycation end products, which cause diabetic complications and are a criterion for evaluating the effectiveness of a treating agent for diabetic complications, and show an excellent therapeutic effect on retina blood vessels, increased occludin, and decreased angiogenic growth factor in actual diabetic retinopathy induced retina. Thus, novel biphenyl compounds according to the present invention can be used effectively as an active ingredient in compositions for preventing or treating diabetic complications such as diabetic retinopathy. | 08-15-2013 |
20130231396 | NOVEL SELF-ASSEMBLING POLYPHENOL-QUINONOID POLYMER DERIVATIVES AND USES THEREOF - The invention relates to novel polyphenol-quinonoid polymer derivatives, methods of synthesizing, compositions and uses thereof. In particular, the invention relates to polyphenol-quinonoid polymer derivatives useful in the treatment of viral infections, notably conditions caused by retroviruses such as human immunodeficiency virus (HIV). | 09-05-2013 |
20130245129 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE - This invention provides compound having a structure of Formula I or Formula II | 09-19-2013 |
20130324615 | BIODEGREDATION SUPPRESSION SOLUTION FOR FORENSIC SAMPLES - A biodegradation suppression system may include an anti-microbial agent, wherein the anti-microbial agent is effective to suppress biodegradation of ignitable liquid residues within a forensic sample. The biodegradation suppression system for use with a forensic sample may also include a solution including triclosan, wherein the solution suppresses biodegradation of ignitable liquid residues within a forensic sample for a period of time. The biodegradation suppression system for use with a forensic sample may also include a solution including triclosan, wherein the solution suppresses biodegradation of gasoline, wherein the solution is effective to allow for identification of at least one component of gasoline within the forensic sample. | 12-05-2013 |
20140080917 | FABRIC CARE COMPOSITION - An aqueous fabric care composition having a thickener and an antibacterial compound. The composition has a high storage stability. The composition has from about 0 wt % to about 5 wt % of anionic surfactant, from about 0 wt % to about 3 wt % of cationic surfactant, from about 0 wt % to about 3 wt % of a non-ionic surfactant, from about 0.01 wt % to about 15 wt % of a thickener, from about 0.01% to about 15% of a non-ionic antibacterial compound having a C log P above about 2 and water. | 03-20-2014 |
20140288186 | Method for lowering blood glucose and method for treating hepatic disease, obesity and diabetes - The present invention provides methods of administering a | 09-25-2014 |
20140296349 | ANTIMICROBIAL CLEANING COMPOSITION - The present invention relates to an antimicrobial cleaning composition comprising at least one sugar surfactant and a compound of the formula (I) as biocide, and to the use of the sugar surfactants for improving the activity of the biocide. | 10-02-2014 |